Jco Precision Oncology
Overview
Jco Precision Oncology is a scientific journal, published since 2017 in English. The journal's country of origin is United States and its primary focus area is oncology.
Details
Details
Abbr.
JCO Precis Oncol
Start
2017
End
Continuing
e-ISSN
2473-4284
Country
United States
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 7562
48
SJR / Ranks: 976
2249
CiteScore / Ranks: 2159
8.20
JIF / Ranks: 1820
4.6
Recent Articles
11.
Krebs E, Weymann D, Ho C, Weppler A, Bosdet I, Karsan A, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400631.
PMID: 39983079
Purpose: Targeted therapy and immunotherapy promise improved survival in patients with advanced melanoma, yet the effectiveness and cost-effectiveness of multigene panel sequencing compared with single-gene testing to guide therapeutic decisions...
12.
Marczyk V, Fazeli S, Dadu R, Busaidy N, Iyer P, Hu M, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400321.
PMID: 39983078
Purpose: Neurotrophic tropomyosin receptor kinase () fusions may act as an oncogenic driver in thyroid carcinomas. Given their low frequency, clinical, pathological, and molecular data on these patients and their...
13.
Liu M, Jagodinsky J, Callahan S, Minne R, Johnson D, Tomlins S, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400690.
PMID: 39983077
Purpose: Metastatic spread of non-small cell lung cancer (NSCLC) to the brain is a commonly occurring and challenging clinical problem, often resulting in patient mortality. Systemic therapies including immunotherapy have...
14.
Matser Y, Samim A, Fiocco M, van de Mheen M, van der Ham M, de Sain-van der Velden M, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400491.
PMID: 39983076
Purpose: Urinary catecholamine metabolites are well-known biomarkers for the diagnosis (Dx) of neuroblastoma, but their clinical significance in determining therapy response during treatment is not well established. Therefore, catecholamines are...
15.
Haberecker M, Ruschoff J, Andriakopoulou C, Gray S, Nackaerts K, de Perrot M, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400675.
PMID: 39938010
Purpose: CD276 (B7-H3) is an immunoregulatory protein that plays an important role in the inhibition of T-cell function. CD276 is overexpressed on a variety of human solid cancer cells with...
16.
Weber U, Einhorn L, Bunn P
JCO Precis Oncol
. 2025 Feb;
9:e2400536.
PMID: 39938009
No abstract available.
17.
Sinan H, Cunningham D, Sleiman E, Petry D, McPhaul T, Visvanathan K, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400494.
PMID: 39938008
Purpose: Current guidelines recommend offering genetic susceptibility testing to individuals with pancreatic cancer regardless of family history, but previous studies have reported only moderate test uptake, highlighting the need for...
18.
Zobeck M, Khan J, Venkatramani R, Okcu M, Scheurer M, Lupo P
JCO Precis Oncol
. 2025 Feb;
9:e2400556.
PMID: 39913888
Purpose: Molecular markers increasingly influence risk-stratified treatment selection for pediatric rhabdomyosarcoma (RMS). This study aims to integrate molecular and clinical data to produce individualized prognosis predictions that can further improve...
19.
Ozgu E, Tokat U, Adibi A, Bilgic S, Aydin E, Tutar O, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400652.
PMID: 39913887
No abstract available.
20.
Gouda M, Wei Z, Rodon J, Davies M, Janku F, Gray R, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400451.
PMID: 39913886
Purpose: Copanlisib, a pan-class phosphatidylinositol 3-kinase (PI3K) inhibitor with activity predominantly against the PI3K-delta and PI3K-alpha isoforms, has shown promising results in preclinical cancer models with PTEN loss. Herein, we...